These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26491810)

  • 1. Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin.
    Joshi AA; Murray TF; Aldrich JV
    J Med Chem; 2015 Nov; 58(22):8783-95. PubMed ID: 26491810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
    Vig BS; Murray TF; Aldrich JV
    J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
    Patkar KA; Murray TF; Aldrich JV
    J Med Chem; 2009 Nov; 52(21):6814-21. PubMed ID: 19807094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
    Bennett MA; Murray TF; Aldrich JV
    J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
    Sirohi S; Aldrich JV; Walker BM
    Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Activity Relationships of [des-Arg
    Ramos-Colon CN; Lee YS; Remesic M; Hall SM; LaVigne J; Davis P; Sandweiss AJ; McIntosh MI; Hanson J; Largent-Milnes TM; Vanderah TW; Streicher J; Porreca F; Hruby VJ
    J Med Chem; 2016 Nov; 59(22):10291-10298. PubMed ID: 27797517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alanine scan of the opioid peptide dynorphin B amide.
    Joshi AA; Murray TF; Aldrich JV
    Biopolymers; 2017 Sep; 108(5):. PubMed ID: 28464209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.
    Patkar KA; Yan X; Murray TF; Aldrich JV
    J Med Chem; 2005 Jul; 48(14):4500-3. PubMed ID: 15999987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor.
    Merg F; Filliol D; Usynin I; Bazov I; Bark N; Hurd YL; Yakovleva T; Kieffer BL; Bakalkin G
    J Neurochem; 2006 Apr; 97(1):292-301. PubMed ID: 16515546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action.
    Aldrich JV; Patkar KA; McLaughlin JP
    Proc Natl Acad Sci U S A; 2009 Oct; 106(43):18396-401. PubMed ID: 19841255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
    Vig BS; Zheng MQ; Murray TF; Aldrich JV
    J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
    Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
    J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
    Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
    J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
    Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
    J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-alkylated derivatives of [D-Pro10]dynorphin A-(1-11) are high affinity partial agonists at the cloned rat kappa-opioid receptor.
    Soderstrom K; Choi H; Berman FW; Aldrich JV; Murray TF
    Eur J Pharmacol; 1997 Nov; 338(2):191-7. PubMed ID: 9456002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of dynorphin a analogues modified in the address sequence.
    Schlechtingen G; DeHaven RN; Daubert JD; Cassel JA; Chung NN; Schiller PW; Taulane JP; Goodman M
    J Med Chem; 2003 May; 46(11):2104-9. PubMed ID: 12747782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynorphin peptides differentially regulate the human kappa opioid receptor.
    Chen Y; Chen C; Liu-Chen LY
    Life Sci; 2007 Mar; 80(15):1439-48. PubMed ID: 17316701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
    Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of kappa opioid receptor ligand potency, efficacy and desensitization using a real-time membrane potential assay.
    Zhao Y; Joshi AA; Aldrich JV; Murray TF
    Biomed Pharmacother; 2021 Nov; 143():112173. PubMed ID: 34536757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.